Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Non-Deal Roadshow (February 2026)
16 slides from Clever Culture Systems's roadshow presentation, Feb 11, 2026
Slide 1: ASX announcement: new company presentation for investor roadshow
Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com ASX:CC5 NEW COMPANY PRESENTATION – INVESTOR ROADSHOW Adelaide, Australia, 11 February 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (CCS or the Company), is pleased to share an
Slide 2: AI-powered microbiology
ASX: CC5 For personal use only AI-powered microbiology Revolutionising microbial quality control in pharmaceutical manufacturing Brent Barnes, CEO and Managing Director February 2026 Clever Culture Systems ASX: CC5 1
Slide 3: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the exp ectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Gi
Slide 4: Snapshot
Snapshot APAS® Independence setting new standard in high-growth pharmaceutical QC automation market Financial stability: High margin ARR >$1m, cashflow positive1, no debt For personal use only Industry leaders backing APAS® technology with global Commercial adoption delivery tailwinds AstraZeneca, B
Slide 5: Problem
Problem Millions of culture plates are manually Incorrect results costly read and reported annually during pharmaceutical manufacturing High cost of failure Up to US$1bn lost revenue1 For personal use only Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastr
Slide 6: Workflow: Environmental monitoring today
Workflow Environmental monitoring today Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Culture plate reading, reporting. Result to release pharmaceutical product Cleanrooms No Growth (pha
Slide 7: Solution
Solution Digital disruption Solution: APAS Automated Plate Assessment For personal use only System Cutting edge AI technology Machine learning for microbiology applications Demonstrated performance Extensive scientific data, faster than microbiologist Improved data integrity Automatic data trails an
Slide 8: Workflow: Environmental monitoring with APAS
Workflow Environmental monitoring with APAS Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Automated culture plate reading No Growth >90% Cleanrooms ➔ Batch release (pharmaceutical manufa
Slide 9: Revenue
Revenue Up to AU$1.5m revenue per APAS Independence sale1 Includes up-front Capex and Annual Recurring Revenue (ARR) streams For personal use only Approx. Product / Service Description Revenue Model Split APAS® Upfront Capex Laboratory (inc. financing 40% Independence Instrumentation options) APAS A
Slide 10: Opportunity
Opportunity Growing Global Laboratory AU$2.8B TAM2 Total Addressable Market for aseptic Automation Market – Forecast to manufacturing microbiology testing. For personal use only grow at 7.2% over next 5 years1 Pharma companies are investing in expanding manufacturing facilities and automation 14 of
Slide 11: AstraZeneca Case Study
Customer AstraZeneca Case Study Enterprise customer – Standardisation across multiple global sites For personal use only 11 instruments • ~1,000 plates per day at large AZ sites purchased and installed • >98% of plates are negative • Occasionally humans make mistakes • Multiple global • APAS resolve
Slide 12: Market: Pharmaceutical manufacturing
Market Pharmaceutical manufacturing: Attractive market for optimisation For personal use only Clever Culture Systems. ASX: CC5 11
Slide 13: Competition
Competition Different automation approach APAS Independence: Incubation and reading technologies end point reader • Requires continuous reading between incubator and imaging platform For personal use only • Incubation size restricts volume capacity (60-132 plates per day capacity) APAS delivers scal
Slide 14: Global footprint: APAS Independence instruments
Global footprint: 28 APAS® Independence instruments1 Asia-Pac: 5 instruments For personal use only USA: 6 instruments Europe: 17 instruments Global pharma customer focus: AstraZeneca, Bristol Myers Squibb, Pfizer, Novo Nordisk, Boehringer Ingelheim, Patheon (Thermo Fisher) APAS sales APAS Training H
Slide 15: Experienced Board and Management
Experienced Board and Management Focused on expansion into pharmaceutical manufacturing industry For personal use only • Board and Management shareholding 20%+ Brent Barnes Rebecca Wilson CEO and MD, AU Chair, AU Aug-16 start Jul-23 start • International experience with healthcare, technology and ph
Slide 16: Outlook
Outlook Growth in customer base New sales to global pharma companies Expected in H2 of FY26 and beyond For personal use only Build customer expansion opportunity Support customer evaluations and establish trusted partnerships APAS® validated in routine use Growth in customers using the technology in
Clever Culture Systems — Non-Deal Roadshow (February 2026) on 6ix